Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants

Simple item page
dc.contributor.authorEzeokoli, Obinna T.
dc.contributor.authorGcilitshana, Onele
dc.contributor.authorPohl, Carolina H.
dc.date.accessioned2021-08-17T06:56:58Z
dc.date.available2021-08-17T06:56:58Z
dc.date.issued2021
dc.description.abstractSevere cases of coronavirus disease 2019 (COVID-19) managed in the intensive care unit are prone to complications, including secondary infections with opportunistic fungal pathogens. Systemic fungal co-infections in hospitalized COVID-19 patients may exacerbate COVID-19 disease severity, hamper treatment effectiveness and increase mortality. Here, we reiterate the role of fungal co-infections in exacerbating COVID-19 disease severity as well as highlight emerging trends related to fungal disease burden in COVID-19 patients. Furthermore, we provide perspectives on the risk factors for fungal co-infections in hospitalized COVID-19 patients and highlight the potential role of prolonged immunomodulatory treatments in driving fungal co-infections, including COVID-19-associated pulmonary aspergillosis (CAPA), COVID-19-associated candidiasis (CAC) and mucormycosis. We reiterate the need for early diagnosis of suspected COVID-19-associated systemic mycoses in the hospital setting.en_ZA
dc.description.versionPublisher's versionen_ZA
dc.identifierhttps://doi.org/10.3390/jof7070545
dc.identifier.citationEzeokoli, O. T., Gcilitshana, O., & Pohl, C. H. (2021). Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants. Journal of Fungi, 7, 545. https://doi.org/10.3390/jof7070545en_ZA
dc.identifier.issn2309-608X (online)
dc.identifier.urihttp://hdl.handle.net/11660/11243
dc.language.isoenen_ZA
dc.publisherMDPIen_ZA
dc.rights.holderAuthor(s)en_ZA
dc.rights.licenseThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
dc.subjectCOVID-19en_ZA
dc.subjectFungal co-infectionsen_ZA
dc.subjectCorticosteroid treatmenten_ZA
dc.subjectCOVID-19-associated candidiasisen_ZA
dc.subjectCOVID-19-associated pulmonary aspergillosisen_ZA
dc.subjectMucormycosisen_ZA
dc.titleRisk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressantsen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ezeokoli_Risk_2021.pdf
Size:
597.87 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.76 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Microbial, Biochemical and Food Biotechnology)